Clinical trials: CYP19
Breast Cancer, Hormone Receptor Positive Tumor
Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA)
In this phase II, multicenter, self-controlled clinical trial, we will evaluate the safety and efficacy of OPERA® for treating anti-aromate inhibitors (AIs) induced arthralgia.
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Arthralgia
- Trial name
- AIA (NCT04161833)
- Testing
- OPERA
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Obesity, Insulin Resistance
Metabolic Effects of Steroids in Obese Men
Subjects will be randomized into 4 study groups: 1. Placebo; 2. Anastrazole and Testosterone; 3. Dutasteride and Testosterone; and 4. Testosterone only.
- Trial name
- NCT00983554
- Testing
- Anastrazole, Testosterone, Dutasteride
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Brest Cancer ER+ and HER2 Negative
De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer
This study is a randomized, open-label, phase II trial designed to evaluate whether alternate-day dosing of letrozole preserves antiproliferative activity compared with standard daily dosing in postmenopausal women with estrogen…
- Trial name
- DELTA (NCT07866430)
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Montefiore Medical Center
Breast Cancer Female, HER2-positive Breast Cancer
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
This study is a randomized, open-label, phase II study, comparing the efficacy and safety of trastuzumab plus aromatase inhibitors, with or without pyrotinib, in the treatment of HR (hormone receptor)+/HER2 (human epidermal…
- Conditions
- Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
- Trial name
- Pyrotinib (NCT03910712)
- Testing
- Pyrotinib, Trastuzumab, Aromatase inhibitor
- Volunteers
- 250 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Aromatase Inhibitors
Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia
The first aim of this comparative, randomized, prospective, multicenter study is to evaluate the analgesic effect at 6 weeks of whole-body cryotherapy, compared to placebo cryotherapy, in patients suffering from arthralgia under…
- Trial name
- CRYOMATASE (NCT05315011)
- Testing
- Whole-body cryotherapy
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Montpellier
ER+ Breast Cancer, Breast Cancer
Alcohol and Breast Cancer (ABC) Trial
This research study is a pilot study, which is the first time investigators are examining the effect of light alcohol consumption on sex hormones among postmenopausal women with estrogen receptor-positive (ER+) breast cancer…
- Conditions
- ER+ Breast Cancer, Breast Cancer, Aromatase Inhibitors
- Trial name
- NCT05423730
- Testing
- White Wine, Grape Juice
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Beth Israel Deaconess Medical Center
Male Breast Cancer, Recurrent Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01153672
- Testing
- vorinostat, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Breast Cancer
Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy
RATIONALE: Gathering information about cognitive function over time in postmenopausal women with breast cancer may help doctors learn about the long-term effects of aromatase inhibitor therapy and plan the best treatment.
- Trial name
- NCT00681928
- Testing
- anastrozole, letrozole, questionnaire administration
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Breast Cancer
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal…
- Trial name
- BELLE-2 (NCT01610284)
- Testing
- Fulvestrant, BKM120
- Where
- 268 sites in United States, Argentina and 27 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Preventing Sexual Dysfunction With Aromatase Inhibitors
Aromatase inhibitors (AIs) are used to try to stop breast cancer from forming or returning after treatment in women who are in menopause and who had breast cancer that was sensitive to the hormone estrogen.
- Trial name
- NCT01603303
- Testing
- Questionnaires, Education Materials, Luvena
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer
Phase II, multicenter, single arm trial to assess the feasibility of first line ribociclib in combination with a non steroidal aromatase inhibitor in women or men aged 70 years-old or older, with hormone receptor positive/HER2…
- Trial name
- FACILE (NCT03944434)
- Testing
- Ribociclib, Aromatase Inhibitors, non steroideal, LHRH agonist
- Where
- Italy
- Volunteers
- 116 people
- Sponsor
- Fondazione Sandro Pitigliani
Atrophic Vaginitis
Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients
The purpose of this study is to assess the long term safety and efficacy of the vaginal application of Gynoflor®, an extremely low dosed estrogen therapy with lactobacilli, on atrophic vaginitis in postmenopausal breast cancer…
- Trial name
- Gynoflor (NCT01370551)
- Testing
- Estriol 0.03 mg, lyophylized lactobacillus
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 16 people
- Sponsor
- Medinova AG
Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness
The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.
The objective of this study is to determine if patients taking aromatase inhibitors (AI), who are experiencing joint discomfort and stiffness, would have reduction in this discomfort and stiffness by participating in a directed…
- Trial name
- NCT02057536
- Testing
- Arm A Directed exercise program, Observation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Christiana Care Health Services
Breast Cancer
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of…
- Trial name
- NCT00516698
- Testing
- polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis
- Where
- 180 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
This is a multicenter, international, randomized, double-blinded, placebo-controlled, Phase II trial. Participants with advanced breast cancer (ABC) or Metastatic Breast Cancer (MBC) who have experienced recurrence or progression…
- Trial name
- NCT01437566
- Testing
- Fulvestrant, GDC-0941, GDC-0980
- Where
- 130 sites in United States, Argentina and 21 more
- Volunteers
- 318 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Impact of a Food Supplement on Musculoskeletal Pain in Women With Breast Cancer Treated With Aromatase Inhibitors.
The aim of this pilot study is to assess the change in pain, measured with the Modified Brief Pain Inventory - Short Form (mBPI-sf), at 4, 8, and 12 weeks.
- Trial name
- DOLFLEX (NCT07199556)
- Testing
- Food supplement
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Arafarma Group, S.A.
Musculoskeletal Pain, Breast Cancer
Phase 3 Study Randomized Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors
Auriculotherapy is a complementary medicine, with few side effects, without contraindication, inexpensive and not very restrictive.Its efficacy has been found in several tests especially for the treatment of intraoperative pain.
- Trial name
- TRIPLE-A (NCT03096041)
- Testing
- Auriculotherapy for analgesic use
- Where
- 7 sites in France
- Volunteers
- 197 people
- Sponsor
- Centre Francois Baclesse
Vaginitis, Dyspareunia
Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.
Atrophic vaginitis is a condition in which the skin lining of the vagina and labia becomes thin and symptoms develop including vaginal itching, vaginal discomfort and dyspareunia.
- Conditions
- Vaginitis, Dyspareunia, Breast Neoplasms
- Trial name
- NCT01122342
- Testing
- Testosterone propionate
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Vermont
Breast Cancer
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
The study is designed to compare the clinical benefit following treatment with aromatase inhibitor in combination with metronomic capecitabine versus aromatase inhibitor alone in women with hormone receptor-positive…
- Trial name
- MECCA (NCT02767661)
- Testing
- Capecitabine, Aromatase Inhibitor
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Sun Yat-sen University